Some level of genes-first mechanism has been demonstrated in CLL patients progressing on covalent BTK inhibitors and undergoing treatment with the non-covalent BTK inhibitor pirtobrutinib. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.